Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV) HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIR ...

Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82% Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the C ...

HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4 Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset of patients with PD-L1 combined positive score (CPS) of 20 or higher, data showed confirmed objective response rate (ORR) of 53%, complete response (CR) rate of 18%, and disease control rate (DCR) of 82% Company will also present promising preliminary progression-free ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________. Commission File Number: 001-38869 HOOKIPA PHARMA INC. (Exact Name of Registrant as Specified in its Char ...

Exhibit 99.1 HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights ● Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedback ● HB-200 program received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) ● Received FDA clearance for Investigational New Drug (IND) applica ...

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first- line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedback HB-200 program received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) Received FDA clearance for Investigational New Drug (IND) application for HB-700 for the treatment of KRAS mutated cancers NEW YORK and VIENNA, May 09, 2024 (GLOBE NEWSWIRE) ...

HOOKIPA公司最新动态 - HOOKIPA宣布了HB-200与pembrolizumab的关键试验设计和协议，以及在2024年ASCO年会上的口头摘要展示[1][2][3] - 该公司计划在2024年第四季度招募第一位患者[2] - HOOKIPA的首席执行官表示公司与FDA和EMA都有良好的合作，有望更快地实现潜在注册[4] - HB-200与pembrolizumab的关键试验设计包括约250名患者，主要终点为Phase 2部分的客观反应率和Phase 3部分的总生存率[4] - 公司可能会根据试验的Phase 2部分数据寻求加速批准[6] - HOOKIPA将举行电话会议，讨论试验设计和临床发展策略[7] - ASCO 2024年会上将展示HB-200的最新数据[9] - HB-200与pembrolizumab获得FDA的快速通道认定和EMA的PRIME认定[10] - HOOKIPA是一家专注于开发新型免疫疗法的临床阶段生物制药公司，旨在对抗或预防严重疾病[10]

HOOKIPA Pharma Inc.（NASDAQ:HOOK）新药申请 - 公司宣布获得美国食品药品监督管理局（FDA）对其HB-700的新药申请（IND）的清关[1] - HB-700项目旨在治疗KRAS突变的肺癌、结肠癌、胰腺癌等，针对这些疾病中最常见的五种KRAS突变：G12D、G12V、G12R、G12C和G13D[2] HOOKIPA的HB-700项目 - 公司将在2024年美国临床肿瘤学会（ASCO）年会上发布HB-700项目的临床前数据摘要[3] - HB-700项目旨在治疗KRAS突变的肺癌、结肠癌、胰腺癌等，是一种复制的2-载体疗法，可针对最常见的KRAS突变（G12D、G12V、G12R、G12C和G13D）[4]

Human Papilloma Virus (HPV-16) luismmolina/iStock via Getty Images On Friday April 19th, shares of Hookipa Pharma (NASDAQ:HOOK) closed at $0.733/s with a valuation ~$72.53M. To be clear, this company is a High Risk/High Reward play and as such, is probably not a suitable investment for most investor’s portfolios. Typically, I would build a 2% position at most in my portfolio for this type of early clinical development target when I am interested. However, in this particular situation, I have increased my ex ...

公司背景 - HOOKIPA Pharma Inc.（NASDAQ:HOOK）是一家专注于开发新型免疫疗法的临床阶段生物制药公司[2] - HOOKIPA的研发重点是基于其专有的阿瑞纳病毒平台，设计用于动员和放大靶向T细胞，从而对抗或预防严重疾病[2] - HOOKIPA的产品线包括其全资拥有的调查性阿瑞纳病毒免疫疗法，针对人类乳头瘤病毒16阳性癌症、KRAS突变癌症和其他未命名适应症[2] - HOOKIPA还计划与吉利德合作开发治疗乙型肝炎和艾滋病的功能性治愈方案[2] 财务信息披露 - 公司通过投资者关系网站、SEC文件、新闻稿、公开电话会议和网络直播等渠道向投资者公布重要财务信息[3]